Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India by Sinha, Prabhat K et al.
MAJOR ARTICLE
Liposomal Amphotericin B for Visceral
Leishmaniasis in Human Immunodeﬁciency
Virus-Coinfected Patients: 2-Year Treatment
Outcomes in Bihar, India
Prabhat K. Sinha,1,a Johan van Griensven,2,3,a Krishna Pandey,1,a Nawin Kumar,1,a Neena Verma,1 Raman Mahajan,2
Pankaj Kumar,2 Ranjeet Kumar,2 Pradeeb Das,1 Gaurab Mitra,2 Laurence Flevaud,4 Cecilia Ferreyra,4 Daniel Remartinez,4
Manuel Pece,4 and Pedro Pablo Palma4
1Rajendra Memorial Research Institute of Medical Science, Patna, Bihar; 2Me ´decins Sans Frontie `res–India, Operational Center Barcelona–Athens, New
Delhi, India; 3Institute of Tropical Medicine, Antwerp, Belgium; and 4Me ´decins Sans Frontie `res, Medical Department, Operational Center Barcelona–
Athens, Barcelona, Spain
Background. Reports on treatment outcomes of visceral leishmaniasis (VL)–human immunodeﬁciency virus
(HIV) coinfection in India are lacking. To our knowledge, none have studied the efﬁcacy of liposomal amphotericin
B in VL-HIV coinfection. We report the 2-year treatment outcomes of VL-HIV–coinfected patients treated with
liposomal amphotericin B followed by combination antiretroviral treatment (cART) in Bihar, India.
Methods. The study included all patients with newly diagnosed VL-HIV coinfection and initiating treatment
with liposomal amphotericin B (20–25 mg/kg in 4–15 days) between July 2007 and September 2010. Kaplan–Meier
estimates of the cumulative incidence of death/treatment failure were calculated.
Results. Fifty-ﬁve patients were included (83.6% male; median age, 35 years; 62% migrant laborers; median
follow-up, 1 year). The median CD4 cell count at VL diagnosis was 66 cells/lL (interquartile range, 38–112). Twenty-
seven patients (49.1%) presented with VL relapse of VL. The overall tolerance of liposomal amphotericin B was
excellent, with no interrupted treatment. Survival by 1 and 2 years after VL treatment was estimated at 85.5%. No
patients had initial treatment failure. The probabilities of VL relapse were 0%, 8.1%, and 26.5% at 0.5, 1, and 2 years
afterVLtreatment,respectively;relapserateswere similarforprimaryVLandVLrelapse.CD4counts,200cells/lLa t
6 months after cART initiation were predictive of subsequent relapse. The mean CD4 cell counts at 6 and 24 months
after cART initiation were 187 and 261 cells/lL, respectively. The rate for retention in HIV care was 83.6%.
Conclusions. Good long-term survival and retention rates were obtained for VL-HIV–coinfected patients
treated with liposomal amphotericin B and cART. Although the initial VL treatment response was excellent, VL
relapse within 2 years remained frequent.
More than 60% of the estimated 500000 annual cases of
visceral leishmaniasis (VL), also known as kala-azar,
occurinthe Indiansubcontinent[1, 2].Inthisregion,as
in EastAfrica, VLis causedby Leishmania donovani,a n d
humans act as the reservoir. In response to this disease
burden, a VL elimination program was launched by the
governments of India, Nepal, and Bangladesh, relying
on outpatient treatment with miltefosine and aiming to
eliminate VL as a public health problem by 2015. With
close to 40% of allcases worldwideand about 80%–90%
of all cases in India occurring in Bihar state, Bihar lies at
the heart of theVL problem regionally as well as globally
[3]. Bihar is one of the most backward and populous
states of India, with poverty, malnutrition, and poorly
functioning health care services chronically embedded.
Human immunodeﬁciency virus (HIV) infection has
been identiﬁed as one of the emerging challenges for VL
control[4].HIV infection dramaticallyincreasesthe risk
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 of progression from asymptomatic infection to VL disease, and
VL accelerates HIV disease progression [5]. In some regions of
East Africa, up to 30% of patients with VL are coinfected with
HIV [5]. Although in early reports VL-HIV coinfection seemed
initially to be virtually nonexistent in India [6–8], a progressive
increase in prevalence has been suggested in more recent studies
from Bihar during the last 5–10 years, with coinfection rates
above 2%–5% reported in some studies [5, 9–13]. In contrast
withthenational decline in HIV prevalence (currently estimated
at 0.3%), data suggest an increasing trend in Bihar, with the
extensive migration of laborers from Bihar to and from major
urban areas put forward as a main driving factor [14].
With the advent of combination antiretroviral treatment
(cART), dramatically improved survival has been reported for
VL-HIV coinfection in high-income countries, although high
relapse rates seemed to persist [5, 15]. Recent studies from East
Africa continue to demonstrate high mortality rates [16–18].
Very limited data are available on VL-HIV coinfection from the
Indian subcontinent. The few, very small studies on short-term
treatment outcomes in India have consistently shown high rates
ofmortality,treatment failureand drug-relatedtoxicity [11–13].
None provided long-term outcome data, possibly because of the
high associated mortality given the relatively limited availability
of cART programs in Bihar until recently. Moreover, none re-
ported outcomes with the use of liposomal amphotericin B,
which combines high efﬁcacy with low toxicity and is currently
the preferential treatment for VL-HIV coinfection according to
World Health Organization (WHO) recommendations [19].
Although liposomal amphotericin B was initially prohibitively
expensive, recent price reductions have made it an option for
low- and middle-income countries [20]. Although the use of
liposomal amphotericin B, combined with cART, could offer
newtreatmentoptions,theeffectivenessofthisapproachhasnot
been documented or explored in the Indian subcontinent.
For assessments of treatment effectiveness in HIV-negative
patients, deﬁnitive cure is usually assessed 6 months after
treatment. However, this assessment is less clear for coinfected
patients, given their high rate of relapse even after the ﬁrst year
of treatment [21]; VL-HIV coinfection seems to be a chronic
condition, requiring long-term monitoring of both conditions.
In this study, we report on the long-term treatment outcomes
(survival and treatment success) in VL-HIV–coinfected patients
treated with liposomal amphotericin B in a VL treatment pro-
gram in Bihar, India.
METHODS
Study Setting
In collaboration with the Indian health authorities, Me ´decins
Sans Frontie `res (MSF) started a VL treatment program in Vaishali
district in Bihar, in July 2007, with liposomal amphotericin B as
ﬁrst-line treatment. Whereas most cases were treated at the
district hospital in Hajipur (district capital), complicated cases
were referred for further diagnostic work-up to the Rajendra
Memorial Research Institute of Medical Sciences (RMRIMS),
located in Patna (Bihar State capital). By 1 September 2010,
6626 patients had received VL treatment within the entire
program, with excellent treatment outcomes reported [22].
Study Design and Population
We conducted a retrospective cohort study using routine pro-
gram data. The study included all patients with newly diagnosed
VL-HIV coinfection who started treatment with liposomal
amphotericin B between July 2007 and September 2010.
Visceral Leishmaniasis Diagnoses and Treatment Protocols
Diagnosis was based on the combination of clinical signs and
symptoms consistent withVL(fever for .2 weeks, splenomegaly
orlymphadenopathy,andweight loss), anda positiverK39rapid
diagnostic test (DiaMed-IT-Leish) for Leishmania antibodies,
after exclusion of malaria and bacterial infections. A provider-
initiated testing and counseling strategy for HIV infection
was implemented at the moment of VL diagnosis. VL-HIV–
coinfected patients were referred to RMRIMS for parasitologic
diagnosis by spleen aspiration, or bone marrow aspiration in
case of contraindications. Parasitologic diagnosis and grading
was done as reported before [22]. For unstable cases, treatment
was usually started at the hospital level, with patients referred to
RMRIMS after stabilization. Consequently, no tissue aspirate
was done in these cases, and diagnosis was based on clinical or
serologic criteria. The same applied when HIV infection was
diagnosed after initiation of VL treatment. Still, all were re-
ferred to RMRIMS for test of cure (TOC) and cART initiation.
Treatment consisted of intravenous liposomal amphotericin
B (AmBisome; Gilead Sciences) administered over 2 hours and
reconstituted according to the manufacturer’s instructions.
A total dose of 20 mg/kg was given, divided over 4 doses given
on days 1, 2, 5, and 10. For less advanced cases, possibly
requiring shorter hospitalization, the same total dose could be
given over 4 consecutive days (days 1–4). For patients relapsing
after having previously received a full course of liposomal am-
photericin B, a total dose of 25 mg/kg was given in 5 doses (days
1, 2, 5, 10, and 15).
Treatment Monitoring and Follow-up
Before and after VL treatment initiation at RMRIMS, full blood
counts, liver function tests, and creatinine measurements were
performed. Follow-up visits and laboratory testing was sched-
uled at 1, 3, 6, 12, and 24 months after treatment initiation.
During these visits, patients were clinically assessed for signs and
symptoms of relapse, with parasitologic evaluation performed
for suspected cases. All patients were clearly informed about the
risk of relapse and strongly counseled to present for evaluation
e92 d CID 2011:53 (1 October) d Sinha et al
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 with the least sign of relapse. To assess for initial parasitologic
cure, TOC was planned for all patients at 1 month after treat-
ment initiation. For some, TOC was not done at the scheduled
visit for programmatic reasons (patients presenting late in the
day; aspiration material unavailable), and TOC was cancelled if
these patients were clinically cured.
Human Immunodeficiency Virus Diagnosis and Antiretroviral
Treatment
HIV diagnosis was based on parallel testing with 2 rapid di-
agnostic tests (SD Bioline-HIV 1/2 and Determine-HIV 1/2)
with conﬁrmation by Western blot analysis (SRL Ranbaxy). All
patients with diagnoses of VL-HIV coinfection were eligible for
cART, as recommended by WHO and national guidelines [19].
The preferential ﬁrst-line regimen consisted of a generic ﬁxed
dose combination containing stavudine, lamivudine, and ne-
virapine. Treatment was initiated after the patient’s general
condition had improved, usually shortly after the end of VL
treatment, with monthly follow-up visits after cART initiation.
A CD4 cell count test was performed before cART initiation
(shortly after VL treatment initiation) and at 6-month intervals
once treatment started. Patients could choose to initiate cART
within the VL-HIV project (the majority) or be transferred to
another antiretroviral treatment (ART) center.
Visceral Leishmaniasis and Human Immunodeficiency Virus
Treatment Outcomes
For VL treatment, initial treatment response was determined
1 month after treatment initiation. Initial cure was deﬁned as
parasite clearance—as demonstrated by TOC—combined with
clinical improvement or clinical cure alone if no TOC was done.
Relapse was deﬁned as recurrence of clinical signs or symptoms
of VL with parasitologic conﬁrmation, after initial or clinical
cure. Patients achieving initial or clinical cure and remaining
relapse free during follow-up were deﬁned as cured. Additional
treatment outcomes included death or being unavailable for
follow-up, deﬁned as patients not presenting for planned visits
and unable to be contacted by phone or through home visits.
Those alive and receiving cART or transferred out were con-
sidered retained in HIV care.
Data Collection and Statistical Analysis
Clinical and laboratory data were systematically collected on
standardized forms. The primary outcome was time to death or
treatment failure (initial or relapse) up to 2 years after VL
treatment. Death and treatment failure were analyzed separately
in secondary analysis. For each patient, person-time at risk was
calculated, starting from the date of VL treatment initiation up
to either the date of death, date of treatment failure, or date of
last visit for those unavailable for follow-up or transferred out,
and 1 September 2010 for the remainder. The cumulative in-
cidence of the outcome was estimated using Kaplan–Meier
methods. For the individual outcome estimates, adjustments
were made for competing risks [23, 24]. Comparisons between
groups were based on the log-rank test. For the main outcome,
independent risk factors were determined in multivariate Cox
regression analysis with backward selection, including those
factors with P values , .05 in univariate analysis. For the sep-
arate outcomes, no multivariate analysis was performed, given
the smaller number of events and the occurrence of groups
without event. To visualize the association of independent
continuousvariables andtheoutcome,a nonparametric method
called LOWESS smoothing was used. Pre- and posttreatment
comparisons were based on the Wilcoxon signed rank test.
Ethical Considerations
The data included in this retrospective analysis constituted part
of routine programmatic data collected for monitoring and
evaluation purposes. The VL-HIV clinical treatment guideline
has been reviewed and approved by the RMRIMS ethics com-
mittee.
RESULTS
Baseline Characteristics
A total of 55 cART-naive VL-HIV infected patients started
treatment with liposomal amphotericin B within the VL pro-
gram(Figure1).Thevastmajority(83.6%)weremale(Table1).
The median CD4 cell count at VL diagnosis was 66 cells/lL.
Sixty-two percent of patients reported that they were migrant
laborers within India, most commonly in Delhi and Kolkata.
Clinical presentation is summarized in Table 2. For 43 pa-
tients (78.2%), diagnosis was parasitologically conﬁrmed. In the
remainder of patients, in whom VL treatment was initiated
before referral to RMRIMS, diagnosis was based on the com-
bination of clinical and serologic data. All but one of these were
primary VL cases with a typical clinical response to VL treat-
ment. In terms of treatment history, 27 (49.1%) patients pre-
sented with VL relapse.
Visceral Leishmaniasis and Human Immunodeficiency Virus
Treatment Outcomes
Overall, tolerance of liposomal amphotericin B was excellent,
with no interruptions of treatment due to intolerance. Treat-
ment was associated with signiﬁcant increases in body weight,
hemoglobin levels, and platelet counts and decreases in spleen
size (Table 3). No signiﬁcant changes in the results of kidney or
liver function tests were observed.
Seven patients (12.7%) died, 3 shortly after initiation of
treatment for suspected opportunistic infections. Four were
reported dead after discharge or during active case ﬁnding.
Five never started cART (see Figure 1). Whereas none of the
55 patients had initial treatment failure, 8 (14.5%) experienced
Treatment of Visceral Leishmaniasis–HIV Coinfection in India d CID 2011:53 (1 October) d e93
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 relapse during follow-up at a median of 1.3 years (interquartile
range, 0.7–1.4) after VL treatment. None of these relapses oc-
curred within the ﬁrst 6 months after treatment. As shown
in Figure 2, CD4 cell counts of .250–300 cells/lL at 6 months
after VL treatment seemed to be associated with a very low risk
of subsequent relapse. Four of the eight patients developing VL
relapse were patients with previous VL relapse and had received
VL treatment (conventional amphotericin B) before the initia-
tion of liposomal amphotericin B within the program. Despite
goodinitial treatment response for allrelapseepisodes, 4 ofthe 8
patients withrelapseexperiencedanotherrelapse withinthe next
3–8 months. All 4 patients had CD4 cell counts ,100 cells/lLa t
6 monthsaftertheﬁrst VLtreatment. The mean CD4 cell counts
at 6, 12, and 24 months after cART initiation were 187 (95% CI,
153–221), 234 (95% CI, 164–303) and 261 (95% CI, 37–486)
cells/lL, respectively.
In terms of overall VL treatment response, the estimated
probabilitiesofdeathortreatmentfailureby6,12,and24months
were 11.7%, 19.8% and 38.3%, respectively. Mortality by 2 years
after VL treatment was estimated at 14.5% (Figure 3). The
probabilities of relapse were 0%, 8.1%, and 26.5% at 6, 12 and
24 months, respectively. The overall rate of retention in HIV
care was 83.6%.
Risk Factor Analysis for Death and Treatment Failure
In univariate analysis, a body mass index (BMI) ,16 kg/m
2 and
diagnosis of tuberculosis were identiﬁed as risk factors for the
combined outcome of death and treatment failure (P , .01 for
both). Only the association with BMI (hazard ratio, 3.6;
95% conﬁdence interval [CI], 1.0–12.9) remained signiﬁcant in
multivariate analysis.
With regard to mortality, CD4 cell counts of ,50 cells/lLa t
VL diagnosis, diagnosis of tuberculosis, and BMI ,16 kg/m
2
were identiﬁed as risk factors in univariate analysis. Relating to
the risk of relapse, a signiﬁcant association was observed with
CD4 cell counts ,200 cells/lL at 6 months after VL treatment.
No signiﬁcant associations were seen between mortality or re-
lapse andcARTuse attimeofVLdiagnosis, historyofrelapse,or
any other baseline characteristic.
Figure 1. Flow chart for patients in this study coinfected with visceral
leishmaniasis (VL) and human immunodeficiency virus (HIV). In addition to
the 6 deaths shown here, 1 patient with relapse was subsequently
reported to have died. cART, combination antiretroviral treatment.
Table 1. Baseline Characteristics of Patients With Visceral
Leishmaniasis (VL) and Human Immunodeficiency Virus (HIV)
Coinfection Treated With Liposomal Amphotericin B, July 2007–
July 2010;
Patient characteristics
Patients, no. (%)
(n 5 55)
Sex
Female 9 (16.4)
Male 46 (83.6)
Age, median (IQR), years 35 (30–40)
Pediatric patients (,15 years old) 2 (3.6)
Caste
a
Forward 6 (10.9)
Backward 35 (63.6)
Lowest 12 (21.8)
Other 2 (3.6)
Risk factor for HIV infection
Migrant laborer 34 (61.8)
High-mobility profession
(driver, transport)
3 (5.4)
Husband with high-mobility profession 4 (7.3)
Other
b 5 (9.1)
None reported 9 (16.4)
CD4 cell count at VL diagnosis,
median (IQR), cells/lL( n5 53)
66 (38–112)
CD4 cell count ,200 cells/lL 48 (90.6)
Baseline body mass index,
median (IQR), kg/m
2
17.1 (15.6–18.5)
Tuberculosis treatment during current
VL episode
9 (16.4)
Time from VL diagnosis to cART initiation,
median (IQR), days (n 5 47)
19 (11–39)
Data represent no. (%) of patients unless otherwise indicated (n 5 55 unless
otherwise stated).
Abbreviations: cART, combination antiretroviral treatment; IQR, interquartile
range.
a The Indian caste system is a system of social organization in which
communities are deﬁned by thousands of hereditary groups. Our patient
population is almost uniformly from relatively ‘‘lower’’ castes. Three
commonly used broader categories were deﬁned, from higher to lower on
the social ladder: forward, backward, and scheduled castes (also called the
‘‘untouchables’’).
b The ‘‘other’’ category included multiple blood transfusions and vertical
transmission (HIV-positive parent).
e94 d CID 2011:53 (1 October) d Sinha et al
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 DISCUSSION
To our knowledge, this study reports on the largest cohort of
VL-HIV–coinfected patients in Asia. Moreover, it is the ﬁrst to
provide long-term outcomes with the use of liposomal am-
photericinB andcARTforVL-HIVcoinfectionfromaresource-
constrained setting. Overall survival was relatively good, initial
treatment failure appearedveryrare.Althoughthe 2-year relapse
ratewassubstantial,allrelapse casesrespondedwelltoliposomal
amphotericin B retreatment. It is also important to note that all
relapse cases would have gone unreported with routine efﬁcacy
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Table 2. Clinical Presentation, Diagnosis, and Treatment Details
in Patients With Visceral Leishmaniasis (VL) and Human
Immunodeficiency Virus(HIV)Coinfection TreatedWith Liposomal
Amphotericin B, July 2007–July 2010
Variable
Patients, no. (%)
(n 5 55)
Main symptoms at presentation (n 5 54)
Fever 54 (100)
Cough 15 (27.8)
Weakness/asthenia 8 (14.8)
Weight loss 7 (13.0)
Abdominal pain/distension 2 (3.7)
Duration of illness, median (IQR), weeks 6 (4–12)
VL diagnosis
Clinical case deﬁnition and positive
rK39 rapid diagnostic test
12 (21.8)
Clinical case deﬁnition, positive rK39
rapid diagnostic test, and parasitologic
conﬁrmation
a
43 (78.2)
Grading of parasite density,
median (IQR) (n 5 42)
4 (3–5)
VL treatment history
First episode (primary VL) 28 (50.9)
Relapse 27 (49.1)
$2 previous VL episodes 8 (14.5)
Time since most recent VL treatment,
median (IQR), months
11.2 (8.2–15.7)
Treatment at most recent VL episode
Amphotericin B 12 (21.8)
Antimonials 6 (10.9)
Liposomal amphotericin B 5 (9.1)
Miltefosine 4 (7.3)
Liposomal amphotericin B treatment regimen
20 mg/kg in 4 doses 50 (90.9)
25 mg/kg in 5 doses 5 (9.1)
Follow-up time after VL treatment,
median (IQR), months
11.4 (3.4–20.3)
Test of cure performed 43 (78.2)
Data represent no. (%) of patients, unless otherwise indicated.
Abbreviations: cART, combination antiretroviral treatment; IQR, interquartile
range.
a Conﬁrmation based on spleen (n 5 40) or bone marrow (n 5 3) aspiration.
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 monitoring, using 6-month outcomes to deﬁne the ﬁnal treat-
ment response.
Mindfulofthereportedhighearlymortality(upto20%–30%)
for patients beginning cART with advanced HIV infection
throughout the world [25, 26], irrespective of VL, the 2-year
survival rates reported for this VL-HIV–coinfected population
are rather encouraging. Moreover, these survival rates compare
favorably with those in a recent study from Ethiopia, which
found a case-fatality rate for coinfected patients of 17.4% by
1 month after VL treatment initiation [18]. Still, given the ,1%
mortality reported in our program for HIV-negative patients
with VL treated with liposomal amphotericin B [22], it remains
true that VL-HIV coinfection is still a deadly combination,
probably mainly because of the advanced HIV disease [27].
This highlights the importance of early detection and treatment
of concurrent opportunistic infections, particularly tuberculosis,
inVL-HIV–coinfectedpatients,alongwithearlycARTinitiation.
The apparentlowratesofinitialtreatment failure inthisstudy
are in contrast with those in another MSF program with a sim-
ilar set-up in Ethiopia; in that program, initial failure occurred
in 33% of HIV-coinfected patients and in even more patients
with relapse, despite the use of high doses of liposomal am-
photericin B (25–30 mg/kg) [28]. However, it needs to be ac-
knowledged that there are also pronounced regional differences
in the treatment efﬁcacy of liposomal amphotericin B in the
general population. In India, high treatment success rates have
consistently been documented in HIV-negative patients at doses
of liposomal amphotericin B that were clearly ineffective in
other regions, including Europe, South America, and East Africa
[29, 30].
In line with ﬁndings from Europe, the relapse rate was
substantial. Longitudinal studies integrating parasite geno-
typing would be needed to quantify the contribution of
reactivation—given ongoing immune suppression—and re-
infection. As reported by others, our data suggest that with
progressive immune recovery—with CD4 cell counts reaching
250–300 cells/lL—the risk of relapse seems to be low [5]. This
underscores the need for timely cART initiation. More sys-
tematic HIV testing should be considered, especially for pa-
tients with relapse or HIV risk factors. On the other hand,
there seems to be a population with poor immune recovery
after cART initiation, with a high risk of (subsequent) relapse.
Close monitoring for VL and VL relapse should be integrated
in ART programs for patients living in or coming from
VL-endemic areas. With relapse predominantly occurring
relatively late after VL treatment, follow-up for several years
after treatment is required, particularly for those with poor
increases in CD4 cell counts after ART initiation.
A number of limitations have to be mentioned. This is a ret-
rospective analysis of a relatively small patient population, using
data from operational settings. In this respect, the incomplete
data on parasitologic diagnosis or TOC are concerning. The
former could have led to erroneous diagnosis of VL, possibly
leading to both under- or overestimation of treatment out-
comes. Still, high speciﬁcity (.95%) of rK39 testing has been
reported [31], also in HIV-infected patients [32]. Incomplete
TOC data could have resulted in underestimation of initial
treatment failurerates, especially inpatients who died. However,
All patients without TOC data manifested a typical response to
antileishmanial treatment, and treatment failure was suspected
for none of these. In any event, initial treatment failure appeared
to be very rare. Viral load data and information on cART and
cotrimoxazole adherence would have strengthened the study
ﬁndings. Finally, detailed analysis of the causes of death might
have been informative.
Figure 2. Association between CD4 cell counts at 6 months after
initiation of treatment for visceral leishmaniasis (VL) and the estimated
risk of subsequent VL relapse (LOWESS graph).
Figure 3. Kaplan–Meier estimates of cumulative incidence of death or
relapse at different time points after initiation of visceral leishmaniasis
(VL) treatment.
e96 d CID 2011:53 (1 October) d Sinha et al
 
b
y
 
g
u
e
s
t
 
o
n
 
M
a
r
c
h
 
9
,
 
2
0
1
2
h
t
t
p
:
/
/
c
i
d
.
o
x
f
o
r
d
j
o
u
r
n
a
l
s
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 More scientiﬁc and programmatic attention should be placed
on VL-HIV coinfection. The expansion of HIV in this VL-
hyperendemic and highly populous state could fuel VL-HIV
epidemics and could contribute to the spread of VL to non-
endemic regions. Although the VL elimination program in the
Indian subcontinent continues to rely on the use of miltefosine,
recently revised WHO guidelines currently recommend liposo-
mal amphotericin B (at a total dose of 10–15 mg/kg) as ﬁrst-line
treatment in this region [19]. Our ﬁndings suggest that liposo-
mal amphotericin B is effective in VL-HIV–coinfected Indian
patients at a total dose of 20 mg/kg. Especially given the risk of
multiple relapses, the risk of inducing drug resistance should be
carefully considered; the use of liposomal amphotericin B at an
increased dose (25 mg/kg) may need to be reviewed as a possi-
bility for patients who experience relapse after treatment at
20 mg/kg. Now that miltefosine and paromomycin are
increasingly available, these drugs could also be considered for
use in second-line regimens. The place of combination therapy
to improve and preserve drug efﬁcacy for coinfected patients
remains to be determined [33].
In conclusion, our ﬁndings support the need for increased
availability of liposomal amphotericin B for VL treatment in
resource-constrained settings, along with highly accessible cART
and treatment for opportunistic infections. Further price re-
ductions for liposomal amphotericin B are much needed to
makethisdrugavailable withinthepublic healthsysteminpoor,
disease-endemic countries.
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